Table 3.
Mixed-effects model assessing the estimated mean difference of cognitive outcomes among APOE ε4/statin status
| Coefficient (95% CI) |
||||
|---|---|---|---|---|
| Variables | ADAS 11 | ADAS 13 | MMSE | MoCA |
| APOE ε4/statin groups | ||||
| APOE ε4 (−/−), statin negative | Ref | Ref | Ref | Ref |
| APOE ε4 (−/−), statin positive | −0.85 (−1.95, 0.25) | −0.93 (−2.50, 0.64) | 0.40 (−0.08, 0.88) | 0.76 (−0.10, 1.62)∗ |
| APOE ε4 (+/+), statin negative | 1.53 (0.28, 2.78)† | 2.95 (1.18, 4.73)† | −0.45 (−1.01, 0.09) | −1.12 (−2.13, −0.12)† |
| APOE ε4 (+/+), statin positive | 0.72 (−0.42, 1.86) | 1.85 (0.23, 3.47)† | −0.29 (−0.79, 0.21) | −0.43 (−1.36, 0.51) |
| APOE ε4 (+/−), statin negative | 2.13 (−0.17, 4.45)∗ | 4.35 (1.08, 7.63)† | −0.84 (−1.85, 0.17) | −1.91 (−3.71, −0.11)† |
| APOE ε4 (+/−), statin positive | 1.48 (−0.16, 2.14)∗ | 3.46 (1.13, 5.80)† | −0.27 (−1.00, 0.45) | −1.33 (−2.76, 0.09)∗ |
| Time (y) | 0.48 (0.35, 0.61)‡ | 0.71 (0.56, 0.86)‡ | −0.26 (−0.33, −0.20)‡ | −0.10 (−0.20, 0.006)∗ |
| APOE ε4/statin group × time interaction | 0.45 (0.39, 0.51)‡ | 0.52 (0.46, 0.59)‡ | −0.25 (−0.27, −0.21)‡ | −0.22 (−0.27, 0.18)‡ |
Abbreviations: ADAS 11, Alzheimer's Disease Assessment Scale 11; CI, confidence interval; MMSE, Mini-Mental State Examination; MoCA, Montreal Cognitive Assessment; Ref, reference.
NOTE. Mixed-effects linear model adjusting for all other variables in the model and age, ethnicity, sex, and marital status.
∗
P values: .05 < P < .10.
†
Statistical significance at P < .05.
‡
Statistical significance at P < .001.